The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia.
The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia.
复制标题
DOI：
10.1186/s12936-016-1637-3
复制
发表时间：
2016-12-05
期刊：
影响因子：
3
通讯作者：
Laufer M
中科院分区：
文献类型：
--
作者：
Mwanza S;Joshi S;Nambozi M;Chileshe J;Malunga P;Kabuya JB;Hachizovu S;Manyando C;Mulenga M;Laufer M
Plasmodium falciparum resistance to anti-malarial drugs remains a major obstacle to malaria control and elimination. The parasite has developed resistance to every anti-malarial drug introduced for wide-scale treatment. However, the spread of resistance may be reversible. Malawi was the first country to discontinue chloroquine use due to widespread resistance. Within a decade of the removal of drug pressure, the molecular marker of chloroquine-resistant malaria had disappeared and the drug was shown to have excellent clinical efficacy. Many countries have observed decreases in the prevalence of chloroquine resistance with the discontinuation of chloroquine use. In Zambia, chloroquine was used as first-line treatment for uncomplicated malaria until treatment failures led the Ministry of Health to replace it with artemether-lumefantrine in 2003. Specimens from a recent study were analysed to evaluate prevalence of chloroquine-resistant malaria in Nchelenge district a decade after chloroquine use was discontinued. Parasite DNA was extracted from dried blood spots collected by finger-prick in pregnant women who were enrolling in a clinical trial. The specimens underwent pyrosequencing to determine the genotype of the P. falciparum chloroquine resistance transporter, the gene that is associated with CQ resistance. Three-hundred and two specimens were successfully analysed. No chloroquine-resistant genotypes were detected. The study found the disappearance of chloroquine-resistant malaria after the removal of chloroquine drug pressure. Chloroquine may have a role for malaria prevention or treatment in Zambia and throughout the region in the future.
登录
查看更多内容
影响因子：
3
作者：
Golassa L;Kamugisha E;Ishengoma DS;Baraka V;Shayo A;Baliraine FN;Enweji N;Erko B;Aseffa A;Choy A;Swedberg G
通讯作者：
Swedberg G
DOI：
10.4269/ajtmh.2003.68.386
发表时间：
2003-04-01
影响因子：
3.3
作者：
Zucker, JR;Ruebush, TK;Campbell, CC
通讯作者：
Campbell, CC
影响因子：
--
作者：
Ndymugyenyi, R;Magnussen, P
通讯作者：
Magnussen, P
恶性疟原虫 K13-Propeller 多态性的全球地图。
DOI：
10.1056/nejmoa1513137
发表时间：
2016-06-23
期刊：
The New England journal of medicine
影响因子：
--
作者：
Ménard D;Khim N;Beghain J;Adegnika AA;Shafiul-Alam M;Amodu O;Rahim-Awab G;Barnadas C;Berry A;Boum Y;Bustos MD;Cao J;Chen JH;Collet L;Cui L;Thakur GD;Dieye A;Djallé D;Dorkenoo MA;Eboumbou-Moukoko CE;Espino FE;Fandeur T;Ferreira-da-Cruz MF;Fola AA;Fuehrer HP;Hassan AM;Herrera S;Hongvanthong B;Houzé S;Ibrahim ML;Jahirul-Karim M;Jiang L;Kano S;Ali-Khan W;Khanthavong M;Kremsner PG;Lacerda M;Leang R;Leelawong M;Li M;Lin K;Mazarati JB;Ménard S;Morlais I;Muhindo-Mavoko H;Musset L;Na-Bangchang K;Nambozi M;Niaré K;Noedl H;Ouédraogo JB;Pillai DR;Pradines B;Quang-Phuc B;Ramharter M;Randrianarivelojosia M;Sattabongkot J;Sheikh-Omar A;Silué KD;Sirima SB;Sutherland C;Syafruddin D;Tahar R;Tang LH;Touré OA;Tshibangu-wa-Tshibangu P;Vigan-Womas I;Warsame M;Wini L;Zakeri S;Kim S;Eam R;Berne L;Khean C;Chy S;Ken M;Loch K;Canier L;Duru V;Legrand E;Barale JC;Stokes B;Straimer J;Witkowski B;Fidock DA;Rogier C;Ringwald P;Ariey F;Mercereau-Puijalon O;KARMA Consortium
通讯作者：
KARMA Consortium
影响因子：
3
作者：
Sipilanyambe, Naawa;Simon, Jonathon L.;Chanda, Pascalina;Olumese, Peter;Snow, Robert W.;Hamer, Davidson H.
通讯作者：
Hamer, Davidson H.